ストックスクリーナーアプリを入手
0.5991
16.68%
-0.1199
前日終値:
$0.719
開ける：
$0.7
24時間の取引高:
478.13K
Relative Volume:
2.19
時価総額：
$53.74M
収益：
-
当期純損益:
$-30.15M
株価収益率:
-0.6584
EPS:
-0.91
ネットキャッシュフロー:
$-31.63M
1週間 パフォーマンス:
-8.55%
1か月 パフォーマンス:
-28.63%
6か月 パフォーマンス:
-68.80%
1年 パフォーマンス:
-53.20%
1日の値動き範囲:
$0.5851
$0.72
1週間の範囲:
$0.55
$0.947
52週間の値動き範囲:
$0.55
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
名前
Context Therapeutics Inc
セクター
電話
267-225-7416
住所
2001 MARKET STREET, PHILADELPHIA
CNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.5991 | 53.74M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-11-25 | 開始されました | D. Boral Capital | Buy |
| 2024-05-16 | 開始されました | Piper Sandler | Overweight |
Context Therapeutics Inc (CNTX) 最新ニュース
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos - Yahoo Finance
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains - Yahoo Finance
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo
Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo
Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Context Therapeutics Unveils Packed Schedule: 4 Elite Healthcare Conferences Coming Up - Stock Titan
Context Therapeutics: 2024 Financial and Strategic Highlights - TipRanks
Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus PT from Brokerages - Defense World
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView
Groundbreaking Cancer Drug Dosing Data: Context Therapeutics Reveals CT-95 Development at AACR 2025 - Stock Titan
JMP maintains $4 target on Context Therapeutics stock By Investing.com - Investing.com UK
What is HC Wainwright’s Forecast for CNTX Q3 Earnings? - Defense World
HC Wainwright Reiterates Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth - Yahoo Finance
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MSN
Piper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
Context Therapeutics Inc. (CNTX) reports earnings - Quartz
Context Therapeutics Secures 3-Year Cash Runway with $94M War Chest, Expands Cancer Pipeline - StockTitan
Context Therapeutics Inc. Doses First Patient in Phase 1 Trial of CTIM-76 and Reports Strong Financial Position Transitioning into 2025 - Nasdaq
Context Therapeutics Reports Full Year 2024 Operating and Financial Results - Bluefield Daily Telegraph
Context Therapeutics Inc. SEC 10-K Report - TradingView
CONTEXT THERAPEUTICS Earnings Preview: Recent $CNTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure - Business Wire
Context Therapeutics (CNTX) to Release Earnings on Thursday - Defense World
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo
Integral Molecular's Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors - StreetInsider.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.33 Average PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Employees - MSN
Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% – Time to Buy? - Defense World
Biotech Giant Context Therapeutics Lures Talent with Sweet Stock Rewards - Elblog.pl
Context Therapeutics Awards Buzzy Stock Options to New Talent, Poised for Tumor-Targeting Breakthroughs - Smartphone Magazine
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Strengthens Team with Strategic Equity Compensation Package - Stock Titan
CNTX’s Stock Journey: What Investors Need to Know About Context Therapeutics Inc’s Performance - The InvestChronicle
Why Did Warren Buffett Just Sell Investments He's Recommended Millions of Others Buy? - The Globe and Mail
Context Therapeutics to Showcase at Top 2025 Investor Conferences - MSN
There's Room to Chase These 3 Stocks Trading Near 52-Week Highs - The Globe and Mail
Centrexion stock hits 52-week low at $0.79 amid market challenges - MSN
Centrexion stock hits 52-week low at $0.9 amid market challenges - MSN
Context Therapeutics Inc (CNTX) Stock: A SWOT Analysis - The News Heater
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MyChesCo
Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) PT at $6.33 - Defense World
Context Therapeutics Inc (CNTX) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):